Most powerful obesity drug yet: People lost up to 25% of weight in trial
Published . Updated .
Retatrutide is a triple-hormone obesity drug simulating GLP-1, GIP, and glucagon.
Directly affected
- PPLI People
Named in this report.
Indirectly affected
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Retatrutide is a triple-hormone obesity drug simulating GLP-1, GIP, and glucagon.
Source: Ars Technica
GE HealthCare Technologies (GEHC) since this story, compared with the market
Since the first closing price after “Most powerful obesity drug yet: People lost up to 25% of weight in trial,” GE HealthCare Technologies (GEHC) is +6.63%. The S&P 500 fund (SPY) is +0.56% over the same days, a +6.08% difference versus the market.
Official trades in GE HealthCare Technologies (GEHC) around 29 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). The transaction date is the publication date. The filing is listed beside the story “Most powerful obesity drug yet: People lost up to 25% of weight in trial.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 18 days before publication, inside 30 days. The filing is listed beside the story “Most powerful obesity drug yet: People lost up to 25% of weight in trial.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 57 days before publication, inside 60 days. The filing is listed beside the story “Most powerful obesity drug yet: People lost up to 25% of weight in trial.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around GE HealthCare Technologies (GEHC)
Companies tied to this story
- GEHC GE HealthCare Technologies
GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence in the 29 Sep 2026 story “Most powerful obesity drug yet: People lost up to 25% of weight in trial.” Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ACHC Acadia Healthcare
For “Most powerful obesity drug yet: People lost up to 25% of weight in trial,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
For “Most powerful obesity drug yet: People lost up to 25% of weight in trial,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
For “Most powerful obesity drug yet: People lost up to 25% of weight in trial,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence in the 29 Sep 2026 story “Most powerful obesity drug yet: People lost up to 25% of weight in trial.” Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
For “Most powerful obesity drug yet: People lost up to 25% of weight in trial,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
GE HealthCare Technologies (GEHC)
“Most powerful obesity drug yet: People lost up to 25% of weight in trial” (29 Sep 2026) reaches GE HealthCare Technologies (GEHC) through this story.
What ties GE HealthCare Technologies (GEHC) to the headline is this: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
A second company, Acadia Healthcare (ACHC), is listed for a different reason: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
The price range for GE HealthCare Technologies (GEHC), and the dates in the story
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. GEHC traded between 63.33 and 71.29 across 20 sessions. The latest close on file is 69.76.
What the saved facts support for GE HealthCare Technologies (GEHC)
46 out of 100
“Most powerful obesity drug yet: People lost up to 25% of weight in trial” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.